Eye care in Japan is expected to see only minimal growth rates in retail volume terms throughout the forecast period, with slightly better performances in retail current value terms. The category is likely to experience both positive and negative pressures.
In April 2024, the Ministry of Health, Labour and Welfare in Japan approved the transition of Santen Pharmaceutical's Hialain S from a first-class to a second-class over-the-counter (OTC) drug. Hialain S, which claims efficacy for eye symptoms such as dry eyes, foreign body sensation, fatigue, and discomfort when wearing contact lenses, has been sold as an OTC product since September 2020.
When considering future product trends, differentiation in areas other than efficacy and ingredients appears to be increasingly important. Due to the limits on composition amounts in OTC products, differentiation based solely on this factor may not be feasible.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Eye Care industry in Japan with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Eye Care industry in Japan, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Eye Care
This category includes artificial tears, eye ointments, eye washes, and eye drops used to treat eye allergies, red eyes, or dry eyes. Excludes all products related to contact lens use and care.
See All of Our DefinitionsThis report originates from Passport, our Eye Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!